




RealRate

MEDICINAL PRODUCTS 2021

Ingevity Corp
Rank 27 of 52





MEDICINAL PRODUCTS 2021

Ingevity Corp
Rank 27 of 52



The relative strengths and weaknesses of Ingevity Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ingevity Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Ingevity Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 91% points above the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	628,700
Assets, Non-Current	101,900
General and Administrative Expense	900,000
Goodwill	818,600
Liabilities, Current	340,400
Liabilities, Non-Current	1,352,000
Other Assets	81,700
Other Compr. Net Income	9,700
Other Expenses	121,100
Other Liabilities	0
Other Net Income	9,000
Other Revenues	1,216,100
Property, Plant and Equipment, Net	703,600
Research and Development	22,600

Output Variable	Value in 1000 USD
Liabilities	1,692,400
Assets	2,334,500
Expenses	1,043,700
Revenues	1,216,100
Stockholders Equity	642,100
Net Income	181,400
Comprehensive Net Income	186,250
Economic Capital Ratio	36%